Hoth Therapeutics, Inc. (HOTH)
| Market Cap | 10.37M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -8.19M |
| Shares Out | 13.17M |
| EPS (ttm) | -1.28 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 541,974 |
| Open | 0.8390 |
| Previous Close | 0.7738 |
| Day's Range | 0.7665 - 0.8295 |
| 52-Week Range | 0.5800 - 3.8000 |
| Beta | 0.64 |
| Analysts | Strong Buy |
| Price Target | 4.00 (+407.87%) |
| Earnings Date | May 13, 2025 |
About HOTH
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It develops HT-001, a topical formulation in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer’s or ot... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for HOTH stock is "Strong Buy." The 12-month stock price forecast is $4.0, which is an increase of 407.87% from the latest price.
News
Hoth Therapeutics Announces Granted Japanese Patent for Novel RNA-Based Cancer Therapy Targeting KIT Gene - Expands Global IP in Precision Oncology Platform
Patent Grant Strengthens Hoth's RNA Therapeutics Pipeline with Broad Claims Covering KIT-Targeted Antisense Oligomers for Oncology and Immunology Applications NEW YORK , April 17, 2025 /PRNewswire/ --...
Hoth Therapeutics Announces Positive Initial Data in Phase 2a Clinical Trial
Reports 50% Reduction in Pruritus (Mean Score Dropped from 1.6 to 0.8) by Day 21 in Open-Label Portion of CLEER HT-001 Phase 2a clinical Trial for Cancer EGFR Inhibitor-Induced Skin Toxicities Key Int...
Hoth Therapeutics Collaborates with Washington University on NIH Grant Application Advancing Alzheimer's Program Using NK-1 Receptor Antagonist HT-ALZ
NEW YORK , April 2, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused clinical-stage biopharmaceutical company, today announced its collaboration with Washington Universit...
Hoth Therapeutics Announces Positive Pre Clinical Data HT-ALZ Shows Promising Breakthrough in Alzheimer's Disease Research Acute treatment with HT-ALZ led to a rapid (~15%) reduction in brain interstitial fluid Aβ levels, within 20 hours
Results underscore the dual-action profile of HT-ALZ—impacting both pathology and symptomology. NEW YORK , April 2, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical com...
Hoth Therapeutics Receives USPTO Filing Receipt for HT-001 Formulation Patent Application, Expanding Existing Patent Coverage
NEW YORK , March 31, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused clinical-stage biopharmaceutical company, today announced that it has received an official Filing Re...
Hoth Therapeutics Advances Cancer Fighting HT-KIT Program with New Patent Filing and Preclinical Study Initiation
NEW YORK , March 26, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on developing first-in-class therapies for allergic and inflammatory diseases, tod...
Hoth Therapeutics Announces Positive Preclinical Results for HT-KIT in Aggressive Cancer Gastrointestinal Stromal Tumors (GIST). HT-KIT Triggered Significant Tumor Cell Death as Early as 24 Hours Post-treatment
New Data Demonstrates Significant Reduction in Tumor Growth and KIT Expression in Preclinical GIST Models Induction of Tumor Cell Death – HT-KIT triggered significant tumor cell death as early as 24 h...
Hoth Therapeutics Announces Plans to Submit Expanded Access Application for HT-001 to Support Cancer Patients in Need
HT-001 is being developed to alleviate the adverse dermatological effects experienced by cancer patients undergoing epidermal growth factor receptor (EGFR) inhibitor treatments. With positive progress...
Hoth Therapeutics Announces Positive Results for HT-001 in Treating EGFR Inhibitor-Associated Papulopustular Eruptions Findings to be Presented at the American Academy of Dermatology 2025 Annual Meeting
The data will be presented at the American Academy of Dermatology (AAD) 2025 Annual Meeting, which takes place March 7-11, 2025 , highlighting HT-001 as a potential breakthrough therapy for EGFR inhib...
Hoth Therapeutics Announces Positive Findings on GDNF's Potential as a Game-Changer in Obesity Treatment and Reduced Fatty Liver Disease
Research Demonstrates GDNF's Ability to Prevent and Reverse Obesity by Enhancing Fat Metabolism and Energy Expenditure Hoth is developing this therapeutic in Partnership with the Department of Vetera...
Hoth Therapeutics Partners with OnTargetx R&D to Advance Research for Cancer fighting HT-KIT Cancer Therapeutic
NEW YORK , Feb. 10, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company dedicated to developing innovative therapies for unmet medical needs, today announced its c...
Hoth Therapeutics Regains Compliance with Nasdaq Listing Requirements
NEW YORK , Jan. 24, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH) (the "Company" or "Hoth Therapeutics"), a biopharmaceutical company, today announced that it has received notification f...
Hoth Therapeutics Expands Intellectual Property Portfolio with Acquisition of New Patent Applications
IP will be used to pursue further indications for HT-001 Cancer Therapeutic NEW YORK , Jan. 21, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company...
Hoth Therapeutics to Attend Sequire Investor Summit January 21-23, 2025
NEW YORK , Jan. 17, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that Robb Knie, Chief Executive Officer, is scheduled to attend the Sequir...
Hoth Therapeutics Responds to Market Rumors and Shareholder Inquiries
The Company affirms that it has no plans for a public or private offering at this time. Hoth's financial position remains robust, with a strong balance sheet that includes over $10 million in cash and...
Why Is Hoth Therapeutics Stock Flying Higher On Tuesday?
On Tuesday, Hoth Therapeutics, Inc. HOTH shared interim safety and efficacy results from its Phase 2a clinical trial of HT-001, designed to address skin toxicities linked to Epidermal Growth Factor Re...
Hoth Therapeutics Achieves Breakthrough in Phase 2a Trial: HT-001 Delivers 100% Success in Combating Cancer Treatment Skin Toxicities
Highlights: 100% of Patients in Cohort 1 Achieve Primary Efficacy Endpoint No Treatment-Related Adverse Effects Observed Preserves Cancer Treatment Efficacy with Zero Dose Reductions NEW YORK , Jan. 7...
Hoth Therapeutics Enters Partnership with the Department of Veterans Affairs to Develop Obesity Treatment
Hoth Therapeutics Enters Exclusive Patent License Agreement with VA and Emory University Hoth Also Expands Its' Intellectual Property to Further Its' Market Opportunity for HT-001 NEW YORK , Dec. 26, ...
Hoth Therapeutics Board of Directors Approves Bitcoin as Treasury Reserve Asset
NEW YORK , Nov. 20, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, today announced that the Company's Board of Directors approved the purchas...
Hoth Therapeutics Announces Update on Cancer Therapeutic HT-KIT Results Suggesting the Treatment Effectively Inhibited Tumor Growth in Preclinical Treatment Study
NEW YORK , Oct. 29, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company dedicated to developing new generation therapies for unmet medical needs, is...
Hoth Therapeutics Awarded Key US Patent for Groundbreaking Alzheimer's Treatment and Prepares for Clinical Trials of HT-ALZ with Formulation Now Underway
NEW YORK , Oct. 15, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on developing innovative treatments, is proud to announce the granti...
Hoth Therapeutics Announces Promising Preclinical Results for Alzheimer's Drug HT-ALZ
Early observations suggest that the vehicle-treated Alzheimer's mice exhibit a larger population of reactive astrocytes, while the HT-ALZ treated groups show fewer reactive astrocytes, pointing to a p...
Hoth Therapeutics Announces Expansion of Clinical Sites for HT-001 Phase 2a Trial
Dana-Farber Cancer Institute in Boston, MA and Montefiore Medical Center in New York, NY Join Clinical Trial NEW YORK , Sept. 5, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-...
Hoth Therapeutics Announces Positive Data from First-of-its-Kind Human Patient Treatment of EGFRI-Associated Skin Toxicities with HT-001
Cancer Patient Ceased Treatment After One Week Due to Rapid Success In the reported case, the patient, a 59-year-old female undergoing treatment at George Washington University for metastatic breast ...
Hoth Therapeutics and Aronnax Inc. Enter Master Services Agreement For HT-KIT Cancer Therapeutic
Aronnax to Determine the Maximum-Tolerated Dose (MTD) Post Intravenous Injection Followed by a Dose Range-Finding Phase of Hoth's Orphan Drug HT-KIT NEW YORK , Aug. 15, 2024 /PRNewswire/ -- Hoth Thera...